Regenerative medicine
Reimbursement routes and past practices for advanced therapy medicinal products in the Netherlands.
Jurriaan Gort, Christine C van Hattem, Floris Logman, Geert W J Frederix, Lotty Hooft, Lourens T Bloem, Renske M T Ten Ham
Published: 202510.1080/17460751.2025.2594314
Abstract
AIM: Achieving market access for advanced therapy medicinal products (ATMPs) requires navigating national reimbursement routes. This is said to be particularly challenging for academic developers and small- and medium-sized enterprises, increasingly…
Preview only. Read the full abstract at the source